HSR21-057: Cost-Effectiveness of Cemiplimab vs Pembrolizumab for the First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (aNSCLC) and Programmed Death-Ligand 1 (PD-L1) Expression ≥50% in the US

Authors:
Andreas Kuznik Regeneron Pharmaceuticals, Inc., Tarrytown, NY

Search for other papers by Andreas Kuznik in
Current site
Google Scholar
PubMed Close
 PhD
,
Meena Venkatachalam Precision HEOR, London, UK

Search for other papers by Meena Venkatachalam in
Current site
Google Scholar
PubMed Close
 MSc
,
Gerasimos Konidaris Sanofi, Reading, UK

Search for other papers by Gerasimos Konidaris in
Current site
Google Scholar
PubMed Close
 MSc
,
Chieh-I Chen Regeneron Pharmaceuticals, Inc., Tarrytown, NY

Search for other papers by Chieh-I Chen in
Current site
Google Scholar
PubMed Close
 MPH
,
Sam Keeping Sanofi, Reading, UK

Search for other papers by Sam Keeping in
Current site
Google Scholar
PubMed Close
 MSc
,
Kokuvi Atsou Sanofi, Chilly-Mazarin, France

Search for other papers by Kokuvi Atsou in
Current site
Google Scholar
PubMed Close
 PhD
,
Yingxin Xu Regeneron Pharmaceuticals, Inc., Tarrytown, NY

Search for other papers by Yingxin Xu in
Current site
Google Scholar
PubMed Close
 PhD
,
Florence Wilson Precision HEOR, Vancouver, BC, Canada

Search for other papers by Florence Wilson in
Current site
Google Scholar
PubMed Close
 MSc
,
Patricia Guyot Sanofi, Chilly-Mazarin, France

Search for other papers by Patricia Guyot in
Current site
Google Scholar
PubMed Close
 PhD
,
Keith Chan Precision HEOR, Vancouver, BC, Canada

Search for other papers by Keith Chan in
Current site
Google Scholar
PubMed Close
 MSc
,
Emily Glowienka Precision HEOR, Boston, MA

Search for other papers by Emily Glowienka in
Current site
Google Scholar
PubMed Close
 MPH
, and
Caitlin Smare Precision HEOR, London, UK

Search for other papers by Caitlin Smare in
Current site
Google Scholar
PubMed Close
 MSc
Volume/Issue:
Volume 19: Issue 3.5
Online Publication Date:
17 Mar 2021
DOI:
https://doi.org/10.6004/jnccn.2020.7794
Restricted access

Corresponding Author: Andreas Kuznik, PhD
  • Collapse
  • Expand
Print ISSN:
1540-1405
Online ISSN:
1540-1413
Publisher:
National Comprehensive Cancer Network
Cover Journal of the National Comprehensive Cancer Network
Copyright:
Copyright © 2021 by the National Comprehensive Cancer Network 2021
Article Category:
Abstract
Print Publication Date:
20 Mar 2021
Online Publication Date:
17 Mar 2021

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 2592 703 160
PDF Downloads 1279 0 0
EPUB Downloads 0 0 0